87421-27-0

Basic information

• Product Name: Butanoic acid, 4-amino-3-[[(1,1-dimethylethoxy)carbonyl]amino]-4-oxo-, phenylmethyl ester, (S)-
• Synonyms: 3-tert-Butoxycarbonylamino-succinamic acid benzyl ester
• CAS NO: 87421-27-0
• Molecular Formula: C16H22N2O5
• Molecular Weight: 322.361
• Mol File: 87421-27-0.mol
• Article Data: 19

Chemical Properties

• Melting Point: 154-156 °C(Solv: ethyl acetate (141-78-6))
• Boiling Point: 528.5±50.0 °C(Predicted)
• Density: 1.188±0.06 g/cm3(Predicted)
• CAS DataBase Reference: Butanoic acid, 4-amino-3-[[(1,1-dimethylethoxy)carbonyl]amino]-4-oxo-, phenylmethyl ester, (S)-(CAS DataBase Reference)
• NIST Chemistry Reference: Butanoic acid, 4-amino-3-[[(1,1-dimethylethoxy)carbonyl]amino]-4-oxo-, phenylmethyl ester, (S)-(87421-27-0)
• EPA Substance Registry System: Butanoic acid, 4-amino-3-[[(1,1-dimethylethoxy)carbonyl]amino]-4-oxo-, phenylmethyl ester, (S)-(87421-27-0)

Safety Data

• Hazardous Substances Data: 87421-27-0(Hazardous Substances Data)

Upstream product

• 7536-58-5 BOC-L-aspartic acid 4-benzyl ester 
• 82825-48-7 α-pentafluorophenyl N-tert-butoxycarbonyl-β-benzyl-L-asparaginate 
• 158010-97-0 Boc-Asp(β-OBzl)-Ser-OMe 
• 24424-99-5 di-tert-butyl dicarbonate 
• 2177-63-1 (S)-2-amino-4-(benzyloxy)-4-oxobutanoic acid 
• 1336-21-6 ammonium hydroxide 
• 541-41-3 chloroformic acid ethyl ester 
• 100-51-6 benzyl alcohol 
• 147291-69-8 4-(benzyloxy)-2-(tert-butoxycarbonylamino)-4-oxobutanoic acid 
• 63228-51-3 L-aspartic acid beta-benzyl ester 

Downstream Products

• 92762-93-1 β-benzyl L-isoasparaginate 
• 92762-94-2 β-benzyl-L-aspartic acid amide trifluoroacetate 
• 208665-38-7 2-((S)-3-Benzyloxycarbonyl-2-tert-butoxycarbonylamino-propionylamino)-malonic acid dimethyl ester 
• 308277-54-5 (2S,3S)-2-[2-((S)-3-Benzyloxycarbonyl-2-tert-butoxycarbonylamino-propionylamino)-2-methoxycarbonyl-acetylamino]-3-methyl-pentanoic acid methyl ester 
• 706785-46-8 methyl 2-(3-benzyloxycarbonyl-2-tert-butoxycarbonylaminopropanoyl)amino-3-oxobutanoate 
• 913094-93-6 β-benzyl N-chloroacetyl-L-isoasparaginate 
• 913094-95-8 β-benzyl N-phosphonoacetyl-L-isoasparaginate 
• 913094-94-7 β-benzyl N-(diethoxyphosphinoyl)acetyl-L-isoasparaginate 
• 706785-47-9 (S)-2-(2-benzyloxycarbonyl-1-tert-butoxycarbonylaminoethyl)-5-methylthiazole-4-carboxylic acid methyl ester 
• 208665-34-3 2-((S)-2-Benzyloxycarbonyl-1-tert-butoxycarbonylamino-ethyl)-5-methoxy-oxazole-4-carboxylic acid methyl ester 
• 150638-21-4 N-α-[8-(nitroguanidino)octanoyl]aspartic acid amide β-benzyl ester 
• 201030-72-0 N-α-[9-(nitroguanidino)nonanoyl]aspartic acid amide β-benzyl ester 
• 1120367-11-4 (S)-benzyl 3-((tert-butoxycarbonyl)amino)-3-cyanopropanoate 
• 74244-17-0 (S)-4-amino-3-((tert-butoxycarbonyl)amino)-4-oxobutanoic acid 

Relevant articles and documents

Dehydromicrosclerodermin B and Microsclerodermin J: Total Synthesis and Structural Revision

The total synthesis of dehydromicrosclerodermin B and microsclerodermin J is described. Efficient approaches to the unusual amino acids in the target molecules were developed on the basis of a Negishi coupling (for Trp-2-CO2H) and Blaise reaction (for Pyrr). An incorrect assignment of the pyrrolidinone stereochemistry of both compounds was confirmed by synthesizing epimers of the proposed structures. The spectroscopic data of these epimers were in complete agreement with those for the naturally derived material.

USE OF CSE INHIBITORS FOR THE TREATMENT OF CUTANEOUS INJURIES OR CONDITIONS AND SLEEP-RELATED BREATHING DISORDERS

no abstract published

CATHEPSIN CYSTEINE PROTEASE INHIBITORS FOR THE TREATMENT OF VARIOUS DISEASES

The present invention relates to compounds capable of inhibiting and/or decreasing the activity of one or more cathepsins, thereby treating and/or preventing various disease states associated with one or more cysteine proteases including, but not limited